Estrone

Target: This ligand targets estrogen receptors ERα/ESR1 and ERβ/ESR2 in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for estrogen receptors ERα/ESR1 and ERβ/ESR2. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings estrogen receptors ERα/ESR1 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• Estrogen Receptor PROTAC Development: Estrone can serve as a steroidal ligand scaffold to recruit estrogen receptor proteins within PROTAC designs. By conjugating Estrone-derived binding elements to an E3 ligase recruiter, researchers can investigate ubiquitination-driven degradation of ERα/ERβ, enabling tunable suppression of estrogen-responsive signaling pathways in cell-based assays.

• ERα/ERβ Degradation Studies: Estrone-based targeting can be used to explore selective degradation of estrogen receptor isoforms. PROTAC constructs incorporating Estrone as the target-binding moiety may help compare degradation potency versus occupancy, clarifying how ligand affinity, linker geometry, and E3 ligase selection influence ER turnover kinetics and downstream transcriptional effects.

• Linker and E3 Ligase Optimization: Estrone is suitable for systematic PROTAC optimization, including varying linker length, composition, and attachment site to maximize productive ternary complex formation. Pairing Estrone with different E3 ligase recruiters allows researchers to map degradation efficiency, stability, and specificity, supporting mechanistic studies of how PROTAC architecture governs ubiquitin-proteasome engagement.

• Mechanistic Ternary Complex Profiling: Estrone-containing PROTACs can be applied to dissect the molecular basis of targeted degradation by measuring ternary complex formation between estrogen receptors, the PROTAC, and E3 ligases. Such studies can use biophysical and proteomic readouts to correlate complex stability with ER degradation extent, informing rational design rules for steroid-based degraders.

Estrone is a estrogen receptor ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Estrone is characterized by phenol or alcohol functionality; steroid or fused polycyclic hydrophobic core. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The hydroxy or phenolic motif can be considered for ether, carbonate, carbamate, or ester linker attachment after SAR verification. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.